Chemical Products List

Bcr-Abl inhibitors

Bcr-Abl inhibitors are pharmaceutical compounds designed to target and inhibit the activity of the Bcr-Abl fusion protein. This fusion protein results from a genetic abnormality known as the Philadelphia chromosome, which is characteristic of chronic myelogenous leukemia (CML) and some acute lymphoblastic leukemias (ALL). The Bcr-Abl fusion protein possesses constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation and survival in affected leukocytes. Bcr-Abl inhibitors work by binding to the ATP-binding site of the Bcr-Abl kinase domain, thereby preventing the phosphorylation of downstream signaling molecules involved in cell growth and survival pathways. By inhibiting Bcr-Abl kinase activity, these inhibitors aim to induce apoptosis (programmed cell death) in leukemia cells harboring the Bcr-Abl fusion protein and to reduce the burden of leukemic cells in affected individuals.